DRUG · Mapped RxNorm record
Dulaglutide
Normalized identity: dulaglutideView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
NCT01394952
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedResearching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
DulaglutideDRUG · verified · RxNorm: dulaglutide
PlaceboDRUG
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
QuébecQuebec, Canada2HoustonTexas, United States1Los AngelesCalifornia, United States1DallasTexas, United States1St LouisMissouri, United States1MiamiFlorida, United States1TorontoOntario, Canada1SeoulSouth Korea1BarcelonaSpain1SeattleWashington, United States1San DiegoCalifornia, United States1ColumbusOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01394952 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.